Company Media

US Defense finishes latest research on Immuron’s Travelan®

16 July 2018

The studies were designed to evaluate Travelan’s ability to neutralise pathogenic bacteria of interest, including Campylobacter, ETEC and Shigella bacterial infections. Travelan was shown to bind and was reactive to all strains of bacteria tested.

No crap: Immuron is one step closer to an anti-gastro pill

16 July 2018

In January, Immuron (ASX:IMC) released a study of its Travelan tablets by the DOD which showed its was effective in preventing travellers diarrhoea in 180 strains of campylobacter.

Big Pharma is watching as Immuron edges towards trial results

26 June 2018

There’s no arguing against the ‘breast is best’ mantra at long-standing Melbourne based biotech Immuron, which bases its therapeutics on the goodness of colostrum (the antibody-rich milk produced by mammals after birth).

Immuron reports positive clinical study results in the fight against fatty liver disease

8 March 2018

Dual-listed early-stage biotech company Immuron (ASX: IMC) has revealed keenly anticipated results for its phase 2 non-alcoholic steatohepatitis (NASH) clinical study. The primary objective of the study was to evaluate the safety and efficacy of IMM-124E.

Shares in Australian pharma Immuron are going nuts

8 March 2018

Shares in pharmaceutical company Immuron Limited surged by 80% when it announced promising results in testing its anti-inflammation drug. The Australian microbiome is developing and commercialising treatments for inflammatory and infectious diseases.

Immuron's IMM-124E shows encouraging action in mid-stage NASH study; shares ahead 81%

8 March 2018

Top-line data showed treatment with IMM-124E (bovine colostrum) produced a statistically significant reduction in serum lipopolysaccharide (LPS) levels compared to placebo. LPS is associated with the progression of NASH.

Immuron’s shares surge on demonstrating proof of concept for liver drug candidate

8 March 2018

Immuron Limited’s (ASX:IMC) (NASDAQ:IMRN) IMM-124E has demonstrated a statistically significant reduction in serum lipopolysaccharide (LPS) levels, a major factor in liver inflammation.

Results in: IMC’s lead drug reduces major factor in liver inflammation

8 March 2018

Results demonstrate excellent safety and tolerability; statistically significant reduction in serum endotoxin/liposaccharide (LPS) levels compared to placebo; statistically significant reduction in mean serum ALT in patients with elevated pre-treatment AL

Blockbuster Results from IMC’s NASH Liver Therapy Trials

8 March 2018

Today, IMC is setting a new standard as far as ‘positive developments’ go, topline results show significant improvement in liver injury and a significant reduction in blood levels of LPS — a known mediator of liver inflammation in patients with NASH.

Immuron reduces liver inflammation

2 March 2018

Immuron Limited (ASX: IMC) said results of its IMM-124E phase II Non-Alcoholic Steatohepatitis (NASH) clinical study were positive. Results demonstrate excellent safety and tolerability; statistically significant reduction in serum endotoxin/liposaccharid

How Do You Recruit Patients Unaware Of Their Disease?

1 March 2018

Immuron’s anti-NASH drug is IMM-124E, a colostrum-based compound. Colostrum is the first secretion (milk) from the mammary glands of cows post birth. Colostrum tends to be high in antibodies, although Immuron uses a very specific kind of colostrum achieve

Immuron's fatty liver disease candidate advancing — 4 insights

14 September 2017

Immuron is making progress on three clinical trials for IMM-124E, its nonalcoholic steatohepatitis and nonalcoholic fatty liver disease treatment. Here's what you should know.

In dash to NASH, Immuron targets the gut not the liver

28 March 2017

Cookies and milk or cookies and colostrum? Immuron is targeting inflammatory bacteria in the gut with an engineered colostrum formulation, designed to prevent the liver damage that leads to NASH.